Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Regeneron nabs FDA 'breakthrough' tag for new Eylea use in diabetics

Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.

UPDATED: With FDA confab looming, Chantix experts can't persuade court to unseal Pfizer records

Next month, the FDA's expert advisers will take another look at Pfizer's stop-smoking drug Chantix. The official agenda: Weigh new data on Chantix's links to psychiatric side effects, and consider changing the black-box warning about those risks.

Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche

So much for home field advantage. Switzerland plans to put the squeeze on drug prices, despite its corporate citizens Roche and Novartis. And the Basel-based companies are none too happy about the idea.

Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics

Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting blockbuster Lipitor.

Balky payers, beware: Gilead eyes $95K-or-so price for Sovaldi combo pill

Gilead Sciences has cracked the door on its pricing for the hepatitis C combo pill it's hoping to roll out next month. And here's the view: No "significant premium" to the current three-drug cocktail that includes Sovaldi, Gilead's current money-minting treatment.

The huge price hike as sales strategy, taken to extremes by Retrophin

How's this for a business plan? Buy an old drug for a rare condition. Raise its price by 20 times. Prepare to reap the sales. What could be wrong with that?

Meet Baxalta, the pharma spinoff Baxter plans to unleash in 2015

When Abbott Laboratories told the world that its spun-off pharma business would bear the AbbVie moniker, there were the usual marketing-speak explanations. Includes the name of its former parent. Adds a syllable that evokes a particular-and-desirable image--in AbbVie's case, life itself. Apparently, Baxter International liked that approach. The Chicago-based healthcare company says it's calling its pharma spinoff-to-be Baxalta.

Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets

Pfizer needs a tax inversion deal. Without one, it can't properly compete with overseas companies, simple as that. And if AstraZeneca doesn't want to play, Pfizer is willing to look elsewhere. Even if "elsewhere" means a generics company.

Free speech, PhRMA? Not in this off-label marketing case, feds say

The pharma industry's free speech stand in a whistleblower lawsuit against Millennium Pharmaceuticals? Not so fast, says the Department of Justice. The First Amendment doesn't protect speech that spawns illegal conduct, federal prosecutors say in their own brief in the case.

Mylan challenges Big Pharma's clot fighters with $300M Arixtra buy

Generics maker Mylan has been laying out billions over the last 12 months for M&A. Now, it has inked a deal for a single drug: Arixtra, an injectable blood thinner that fights clots in the legs and lungs.